v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 34,528 $ 27,003
General and administrative 12,468 7,337
Total operating expenses 46,996 34,340
Loss from operations (46,533) (33,177)
Other income/(expense):    
Interest and investment income 6,265 3,791
Loss on investment in former related party (302) (5)
Loss on currency exchange, net (15) (22)
Other expense (249) (98)
Total other income 5,699 3,666
Net loss $ (40,834) $ (29,511)
Net loss per share attributable to common stockholders, basic $ (0.85) $ (0.82)
Net loss per share attributable to common stockholders, diluted $ (0.85) $ (0.82)
Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic 48,032,742 35,790,700
Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, diluted 48,032,742 35,790,700
Comprehensive loss:    
Net Income (Loss) $ (40,834) $ (29,511)
Other comprehensive (loss)/income:    
Unrealized (loss)/gain on marketable securities (1,064) 164
Total other comprehensive (loss)/income (1,064) 164
Total comprehensive loss (41,898) (29,347)
License [Member]    
Revenues:    
Revenues $ 463 $ 1,163